Paper40326484
Can Methotrexate Monotherapy Achieve Clinical Remission in Patients with Active Rheumatoid Arthritis? A Model-Based Meta-Analysis.
Chen S and 5 others. J Clin Pharmacol, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Can Methotrexate Monotherapy Achieve Clinical Remission in Patients with Active Rheumatoid Arthritis? A Model-Based Meta-Analysis. Papers, record 40326484. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40326484
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Methotrexate | Major topic |
| Arthritis, Rheumatoid | Major topic |
| Antirheumatic Agents | Major topic |
| Humans | |
| Remission Induction | |
| Randomized Controlled Trials as Topic | |
| Treatment Outcome | |
| C-Reactive Protein | |
| Blood Sedimentation |
Source PubMed
References93
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37180723 | The effect of JuanBiQiangGu granules in combination with methotrexate on joint inflammation in rheumatoid arthritis: a randomized controlled trial. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37180723 | PubMed |
| 2 | 23053688 | A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis. | Clin Rheumatol | 2013 | https://conductscience.org/library/papers/23053688 | PubMed |
| 3 | 10573044 | Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. | Arch Intern Med | 1999 | https://conductscience.org/library/papers/10573044 | PubMed |
| 4 | 23294500 | Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. | Lancet | 2013 | https://conductscience.org/library/papers/23294500 | PubMed |
| 5 | 15641102 | Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. | Arthritis Rheum | 2005 | https://conductscience.org/library/papers/15641102 | PubMed |
| 6 | 11096165 | A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. | N Engl J Med | 2000 | https://conductscience.org/library/papers/11096165 | PubMed |
| 7 | 36642813 | Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making. | CPT Pharmacometrics Syst Pharmacol | 2023 | https://conductscience.org/library/papers/36642813 | PubMed |
| 8 | 17235556 | Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. | Rheumatol Int | 2007 | https://conductscience.org/library/papers/17235556 | PubMed |
| 9 | 32907614 | The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial. | Arthritis Res Ther | 2020 | https://conductscience.org/library/papers/32907614 | PubMed |
| 10 | 26139202 | Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. | Clin Rheumatol | 2015 | https://conductscience.org/library/papers/26139202 | PubMed |
| 11 | 19369462 | Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. | J Rheumatol | 2009 | https://conductscience.org/library/papers/19369462 | PubMed |
| 12 | 19180516 | Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. | Arthritis Rheum | 2009 | https://conductscience.org/library/papers/19180516 | PubMed |
| 13 | 24976447 | Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis. | Clin Ther | 2014 | https://conductscience.org/library/papers/24976447 | PubMed |
| 14 | 12154206 | Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. | Rheumatology (Oxford) | 2002 | https://conductscience.org/library/papers/12154206 | PubMed |
| 15 | 22739990 | Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. | Ann Rheum Dis | 2013 | https://conductscience.org/library/papers/22739990 | PubMed |
| 16 | 9374925 | Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. | Br J Rheumatol | 1997 | https://conductscience.org/library/papers/9374925 | PubMed |
| 17 | 23011358 | A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. | Mod Rheumatol | 2013 | https://conductscience.org/library/papers/23011358 | PubMed |
| 18 | 31908843 | Correction: Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study. | RMD Open | 2019 | https://conductscience.org/library/papers/31908843 | PubMed |
| 19 | 22012969 | Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. | Ann Rheum Dis | 2012 | https://conductscience.org/library/papers/22012969 | PubMed |
| 20 | 37377385 | Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial. | Int J Rheum Dis | 2023 | https://conductscience.org/library/papers/37377385 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CRP | 1401 | PubTator's text mining | https://conductscience.org/library/genes/1401 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40326484
GET https://conductscience.org/api/papers/v1/40326484/references?page=2